CMS Health Policy Brief

Headline

CMS finalizes Contract Year 2027 Medicare Advantage and Part D rule, advancing prescription payment plan, dual-eligible reforms, and revised Star Ratings methodology

Executive Summary

The Centers for Medicare & Medicaid Services has published its Contract Year 2027 final rule for the Medicare Advantage program, the Medicare Prescription Drug Benefit program, and PACE plans, finalizing approximately two dozen distinct policy provisions spanning prescription drug coverage, the Medicare Prescription Payment Plan, dual eligible special needs plans (D-SNPs), revised Star Ratings methodology, and operational requirements for plan-provider integration. The rule also implements selected technical changes to existing CY2026 policies, with bid submission and beneficiary notification timelines tied to the new framework.

Key Regulatory Signals

• Star Ratings Methodology Update: CMS finalized changes to the Star Ratings calculation methodology affecting how outlier measures are weighted and how guardrails apply to year-over-year score volatility, with direct implications for plan quality bonuses and benchmarking. Plans positioned near the 4-star threshold should reassess their measurement strategies under the revised methodology before the next bid cycle.
• Prescription Payment Plan Operational Standards: The rule codifies operational standards for the Medicare Prescription Payment Plan, including beneficiary opt-in mechanics, monthly billing administration, transition rules at year-end, and pharmacy notification obligations. Part D sponsors must ensure pharmacy network agreements, point-of-sale systems, and member communications align with the finalized framework before the CY2027 plan year.
• D-SNP Integration and State Coordination: CMS strengthened requirements for dual eligible special needs plan integration with state Medicaid programs, including standardized care coordination obligations, beneficiary notification rules at plan transitions, and requirements for D-SNPs to share certain encounter data with state Medicaid agencies. This advances the multi-year CMS strategy to align Medicare and Medicaid for dual eligibles.
• Plan-Provider Integration: New operational requirements address plan-provider relationship management, including timely network adequacy reporting, prior authorization process standards, and gold-card mechanisms for low-denial providers. These requirements operationalize patient-level access protections within the existing MA framework rather than expanding network adequacy regulations.
• AI Provision Deferred to Future Rulemaking: CMS explicitly declined to finalize the proposed AI guardrails provision for Medicare Advantage, signalling that AI-specific MA regulation will be addressed in dedicated future rulemaking rather than embedded in the CY2027 cycle. MA plans deploying AI for utilization management should monitor for that future rulemaking and continue to apply existing nondiscrimination and beneficiary protection standards.

Regulatory Delta

CMS's annual MA rule cycle is the principal operational lever through which Medicare program policy is implemented year-to-year. The CY2027 rule continues the structural reforms initiated in the CY2024-2026 cycles around D-SNP integration, prior authorization standards, and Inflation Reduction Act prescription drug benefit redesign. By deferring the AI provision while finalizing the operational reforms, CMS signals that the MA framework's next strategic axis (AI-specific regulation) will be the subject of a standalone rulemaking, while operational and quality measurement reforms remain on the annual cycle. The rule's Federal Register publication on 6 April 2026 starts the bid cycle clock for CY2027 plan submissions and triggers the operational reconfiguration timeline for sponsors, network providers, and state Medicaid agencies.

Materiality Classification

High — Final rule codifying the operational and quality measurement framework for the Medicare Advantage program for CY2027, with direct implications for plan bid strategy, Star Rating positioning, prescription drug benefit administration, and dual-eligible care coordination across approximately 32 million MA enrollees and the broader Medicare ecosystem.

Time Horizon

Immediate — Rule is effective on its publication date with provisions phasing in for the CY2027 plan year; bid submissions for CY2027 will be governed by the finalized framework, requiring plans to update bid models, member materials, network adequacy submissions, and pharmacy operations now.

Intelligence Outlook

Monitor CMS for the Star Ratings technical specifications update reflecting the methodology changes, and for the proposed Notice of Benefit and Payment Parameters for CY2027. Track the announced dedicated AI rulemaking and any parallel state actions on Medicaid managed care. Assess plan operational systems for prescription payment plan readiness ahead of the CY2027 enrollment cycle.